NUS Links:
A recent study has uncovered that blocking the immune checkpoint protein CD47, long recognised for enabling immune clearance of cancer cells via phagocytosis, also activates a distinct cell death pathway
As we age, stem cells in the brain — responsible for repair and renewal—become less active. Researchers, led by N2CR member Dr Derrick Ong, discovered that a protein called DMTF1
We are pleased to share that Prof. Goh Boon Cher and A/Prof. Wang Lingzhi have published a new edited volume with World Scientific titled Organoids: Advancements in Drug Discovery and Precision
Acute myeloid leukaemia (AML) is a fast-growing blood cancer that often becomes resistant to standard treatments. This resistance is linked to proteins that prevent cancer cells from dying. A new
Treatment of relapsed/refractory non-Hodgkin’s lymphoma (R/R-NHL) remains one of the most difficult challenges in haematologic malignancies, with many patients exhausting standard therapies and facing limited treatment options. In a final
Sorafenib is a first-line therapy used to treat advanced liver cancer, but its effectiveness is often reduced due to resistance in cancer cells. This study co-led by N2CR member, A/Prof
Venetoclax (VEN) is a targeted therapy used to treat chronic lymphocytic leukemia and acute myeloid leukemia. It works by blocking Bcl-2, a protein that prevents cells from undergoing programmed cell
A Phase I clinical trial, led by N2CR clinician-scientist A/Prof David Tan, tested a new drug combination—Selinexor, nivolumab (NIVO), and ipilimumab (IPI)—in Asian patients with advanced solid tumours/cancers and had
Multiple myeloma (MM) is a type of blood cancer that originates from abnormal plasma cells in the bone marrow, leading to serious complications such as bone damage, anaemia, kidney dysfunction,
Multiple primary cancers (MPC) often indicate a hereditary cancer predisposition syndrome. In a study led by Prof Lee Soo Chin, 19% of 3514 cancer patients who underwent germline genetic testing